“Long-Term Improvements Observed in Tralokinumab-Treated Patients with Moderate-to-Severe Atopic Dermatitis: an ECZTEND Interim Analysis” (2021) SKIN The Journal of Cutaneous Medicine, 5(6), p. s59. doi:10.25251/skin.5.supp.59.